ES2057759T3 - Composicion de iontoforesis para aumentar la concentracion de agentes activos en la piel. - Google Patents

Composicion de iontoforesis para aumentar la concentracion de agentes activos en la piel.

Info

Publication number
ES2057759T3
ES2057759T3 ES91302219T ES91302219T ES2057759T3 ES 2057759 T3 ES2057759 T3 ES 2057759T3 ES 91302219 T ES91302219 T ES 91302219T ES 91302219 T ES91302219 T ES 91302219T ES 2057759 T3 ES2057759 T3 ES 2057759T3
Authority
ES
Spain
Prior art keywords
skin
concentration
increase
active agents
iontophoresis composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91302219T
Other languages
English (en)
Inventor
Burton H Sage Jr
James E Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Becton Dickinson and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/653,204 external-priority patent/US5334138A/en
Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co
Application granted granted Critical
Publication of ES2057759T3 publication Critical patent/ES2057759T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Control Of El Displays (AREA)

Abstract

ESTA INVENCION EXPONE METODOS Y COMPUESTOS PARA POTENCIAR UNA CONCENTRACION EN LA PIEL DE AGENTES ACTIVOS IONTOFORETICOS LIBERADOS. ESTOS COMPUESTOS SON COMPOSICIONES FARMACEUTICAMENTE ACEPTABLES PARA UNA LIBERACION IONTOFORETICA QUE COMPRENDE UNA CANTIDAD POTENCIADORA DE CONCENTRACION EN LA PIEL DE UN VASOCONSTRICTOR Y UN AGENTE ACTIVO. ESTOS METODOS COMPRENDEN AÑADIR UNA CANTIDAD POTENCIADORA DE CONCENTRACION EN LA PIEL DE UN VASOCONSTRICTOR PARA UN AGENTE ACTIVO Y LIBERAR MEDIANTE IONTOFORESIS.
ES91302219T 1990-03-15 1991-03-15 Composicion de iontoforesis para aumentar la concentracion de agentes activos en la piel. Expired - Lifetime ES2057759T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49406290A 1990-03-15 1990-03-15
US07/653,204 US5334138A (en) 1990-03-15 1991-02-08 Method and composition for increased skin concentration of active agents by iontophoresis

Publications (1)

Publication Number Publication Date
ES2057759T3 true ES2057759T3 (es) 1994-10-16

Family

ID=27051283

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91302219T Expired - Lifetime ES2057759T3 (es) 1990-03-15 1991-03-15 Composicion de iontoforesis para aumentar la concentracion de agentes activos en la piel.

Country Status (11)

Country Link
EP (1) EP0448299B1 (es)
JP (1) JPH0761957B2 (es)
AT (1) ATE106244T1 (es)
AU (1) AU643760B2 (es)
DE (1) DE69102174T2 (es)
DK (1) DK0448299T3 (es)
ES (1) ES2057759T3 (es)
FI (1) FI911269L (es)
IE (1) IE64891B1 (es)
NO (1) NO911022L (es)
NZ (1) NZ237332A (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023748A1 (en) * 1993-04-08 1994-10-27 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
WO1995028145A1 (en) * 1994-04-18 1995-10-26 The Procter & Gamble Company Iontophoretic delivery of bisphosphonates to the alveolar bone
AU4175197A (en) * 1996-09-04 1998-03-26 Becton Dickinson & Company Iontophoretic method of using phenylephrine to improve the effect of local anesthetics
CA2562932A1 (en) * 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
US20070093743A1 (en) * 2005-09-30 2007-04-26 Vyteris, Inc. Iontophoresis Drug Delivery Device Providing Acceptable Depth and Duration of Dermal Anesthesia
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
JP6371073B2 (ja) * 2013-02-22 2018-08-08 帝國製薬株式会社 イオントフォレシスで麻酔剤（局所麻酔薬）を導入する際に使用するパッチ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU609769B2 (en) 1987-02-10 1991-05-09 Drug Delivery Systems Inc. Electrolytic transdermal delivery of proteins
US5013293A (en) * 1987-05-28 1991-05-07 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
US5334138A (en) * 1990-03-15 1994-08-02 North Carolina State University Method and composition for increased skin concentration of active agents by iontophoresis

Also Published As

Publication number Publication date
EP0448299A3 (en) 1991-12-27
IE64891B1 (en) 1995-09-20
EP0448299A2 (en) 1991-09-25
FI911269A7 (fi) 1991-09-16
AU7280191A (en) 1991-09-19
NO911022D0 (no) 1991-03-14
AU643760B2 (en) 1993-11-25
EP0448299B1 (en) 1994-06-01
ATE106244T1 (de) 1994-06-15
NO911022L (no) 1991-09-16
NZ237332A (en) 1993-07-27
FI911269A0 (fi) 1991-03-14
DK0448299T3 (da) 1994-06-20
DE69102174T2 (de) 1994-09-08
FI911269L (fi) 1991-09-16
JPH0761957B2 (ja) 1995-07-05
IE910716A1 (en) 1991-09-25
DE69102174D1 (de) 1994-07-07
JPH0597709A (ja) 1993-04-20

Similar Documents

Publication Publication Date Title
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
AR013488A1 (es) COMPOSICIoN GERMICIDA ACUOSA PARA EL TRATAMIENTO O PREVENCIoN DE ENFERMEDADES INFECCIOSAS DE LAS PEZUNAS DE ANIMALES, Y USO DE DICHA COMPOSICIoN
ES2113223T3 (es) Utilizacion de un antagonista de substancia p en una composicion topica como agente antitranspirante.
CU23241B7 (es) 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos
ES2141050B1 (es) Composicion blanqueadora dental.
PT1039912E (pt) Agentes angiostaticos e composicoes para tratar glaucoma glc1a
GT199700074A (es) Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona
GT199800037A (es) Combinaciones para diabetes de sulfonilurea - glitazona.
MX9702415A (es) Extractos de cocoa antineoplastica y metodos para elaborar y usar los mismos.
ES2099977T3 (es) Composiciones de liberacion prolongada para tratar enfermedades periodontales.
ES2178250T3 (es) Derivados de aminofenol y su utilizacionm en cosmetica.
ES2045110T3 (es) Mejoras en o relacionadas con antagonistas de leucotrienos.
ES2175414T3 (es) Composiciones cosmeticas que contienen un elastomero de siloxano.
ES2195382T3 (es) Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
ES2147924T3 (es) Composicion terapeutica que comprende un antigeno o un generador in vivo de un compuesto que comprende una secuencia de aminoacidos.
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ES2175332T3 (es) Dentifrico anticalculos que contiene pirofosfato altamente soluble.
MX9703281A (es) Un sistema de suministro para agentes antimetanogenicos.
ES2057759T3 (es) Composicion de iontoforesis para aumentar la concentracion de agentes activos en la piel.
ES2137044T3 (es) Utilizacion de derivados de oxazolidinona como agentes antipenetrantes en una composicion cosmetica y/o dermatologica.
ES2167853T3 (es) N-aril 2-hidroxi alquilamidas.
ES2120801T3 (es) Composicion para la deformacion permanente de las fibras queratinicas, que contienen un antagonista de substancia p o un antagonista de cgrp.
BR9610930A (pt) Composição depilatória incluindo uma quantidade funcional de um agente tixoitrópico, e, uso da quantidade funcional de um agente tixotrópico.
GT199800149A (es) Formulaciones parasiticidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 448299

Country of ref document: ES